Compare BTAI & JG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTAI | JG |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 29.3M |
| IPO Year | 2018 | 2018 |
| Metric | BTAI | JG |
|---|---|---|
| Price | $0.07 | $6.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 11.2M | 4.0K |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $3.20 |
| 52 Week High | $3.19 | $9.87 |
| Indicator | BTAI | JG |
|---|---|---|
| Relative Strength Index (RSI) | 19.82 | 50.05 |
| Support Level | N/A | $5.50 |
| Resistance Level | $1.22 | $6.89 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 0.57 | 0.00 |
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates in one segment and generates revenues from SAAS Businesses.